Dr. Manish Shah has pursued a career in Medical Oncology with a primary focus on clinical translational medicine in GI Oncology that melds his research experience at the bench with patient care.
Dr. Linnie Golightly successfully competed for an R01 grant, entitled "Endothelial Progenitor cells and the Pathogenesis of Cerebral Malaria," and also secured funding through the Gates Challenge Grants with Alberto Bilenca at the Ben-Gurion University in Israel and John March at Cornell in Ithaca to develop a point-of-care test of malaria by a cell phone imaging probe and a novel cholera vaccine based upon in vivo bacterial communication pathways.
A molecular trigger involved in lung regeneration has been uncovered. Investigators – including Dr. Ronald G. Crystal (Chief of Pulmonary and Critical Care Medicine) and Dr. Shahin Rafii (Professor of Medicine/Medicine & Genetics) – have published their findings in Cell. The discovery is part of a labyrinth of advances toward a fuller understanding of the process of lung regeneration.
Dr. Mohamad F. Jamiluddin, a former fellow in the Division of Hematology and Medical Oncology, obtained a patent and produced several research papers in the field of HIV-AIDS within his first two years of training. His journey – emigrating from India to America – is featured in a documentary premiering on HBO, July 4, 2011.
Hepatitis C virus can be transmitted a number of ways, including piercings/tattoos and certain methods of recreational drug use. Dr. Andrew Talal has been invited to join the Division of Viral Hepatitis at the Centers for Disease Control and Prevention in an external advisory group, analyzing whether to recommend HCV testing for people born between 1945 and 1965.
Researchers have pinpointed a biomarker of early-stage emphysema that could provide an advanced new diagnostic tool. Senior author Ronald G. Crystal, M.D., and colleagues published findings that are promising for early detection of emphysema, which affects 2 million people in the United States each year and is irreversible beyond a certain point.
Acute myelogenous leukemia (AML), with more than 12,000 new diagnoses each year, is a particularly stealthy cancer. But a team of researchers led by Ari M. Melnick, M.D., Associate Professor of Medicine at Weill Cornell Medical College, have caught it in the act.
Known for his unconventional approach in the field of tuberculosis research, Dr. Rhee has been working at the molecular level studying Mycobacterium tuberculosis (Mtb) since 2006. He has pursued a course of study that challenges longstanding assumptions about the basic biology of Mtb, the causative agent of TB-with a particular interest in the biological basis of latency.
Research from the laboratory of Ari M. Melnick, M.D. has resulted in a promising new combinatorial therapy for diffuse large B cell lymphoma, an aggressive and rapidly progressive cancer that affects approximately 21,000 new people each year. This research, published in The Journal of Clinical Investigation, may hold significant implications for patient survival rates.
Ira M. Jacobson, M.D., the lead investigator of the ADVANCE trial, reported breakthrough findings at the 61st Annual Meeting of the American Association for the Study of Liver Disease in Boston on November 2, 2010. Adding a protease inhibitor – telaprevir – to the standard first-time treatment given to patients with hepatitis C resulted in a superior success rate.
